Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1136694 | 0.97 | GNAI3 (0.48) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL1136691 | 0.97 | GNAI3 (0.48) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| SCHEMBL382920 | 0.93 | ALDH1A1 (0.56) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| SCHEMBL1412231 | 0.91 | MCHR1 (0.41) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| SCHEMBL14417813 | 0.91 | GNAI3 (0.41) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| SCHEMBL14275787 | 0.91 | ALDH1A1 (0.61) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| SCHEMBL1412233 | 0.91 | MCHR1 (0.41) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| SCHEMBL2437206 | 0.87 | MEN1 (0.57) | MEN1TP53KMT2A | |
| SCHEMBL14417815 | 0.85 | GNAI3 (0.38) | GNAI3GNAO1GNAI1ALDH1A1CHRM2 | |
| SCHEMBL1412129 | 0.84 | MCHR1 (0.43) | GNAI3GNAO1GNAI1ALDH1A1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687851-B | Organic compounds | NOVARTIS AG | 2013-02-27 | — | — | CN | disclosed |
| US-8318935-B2 | Organic compounds 75074 | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2018388-B9 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2332933-A1 | Epithelial sodium channel (ENaC) inhibitors | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2018388-B1 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| EP-2155721-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| CN-101687851-A | organic compounds | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| EP-2155721-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-2018388-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008135557-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007121924-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | GNAI3 3560/4885GNAO1 1187/4885GNAI1 2959/4885 |
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | SCNN1A, TRPM4, TRPV4 | GNAI3 2627/4885GNAO1 978/4885GNAI1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.